Menu Close

Trending

Merck makes circular RNA play with $3.5bn Orna alliance
On heels of new data, Gilead pays $455m for Asian Trodelvy rights
Roche eyes April FDA verdict on Polivy as first-line lymphoma therapy
Digital health’s rapid growth spurt comes home to roost
FDA grants swift review to Lynparza in first-line prostate cancer

Akcea Therapeutics

NICE1

Market Access/ News/ News

NICE relents and okays Akcea’s rare disease drug Waylivra for NHS use

, , , , , , 0 Comment

Patients with the rare disease familial chylomicronemia syndrome (FCS) will be able to access treatment with Akcea’s Waylivra

X
NICE relents and okays Akcea’s rare disease drug Waylivra for NHS use
https://pharmaphorum.com/news/nice-relents-and-okays-akceas-rare-disease-drug-waylivra-for-nhs-use/

Login

CONTINUE TO SITE >
X
Close in 10 seconds